Application of Neo-Bioscore to predict survival in breast cancer patients receiving Neoadjuvant chemotherapy.
Association of Breast Surgery ePoster Library. Khan S. 05/13/19; 257190; P148
Sohail Khan
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Discussion Forum (0)
Rate & Comment (0)
P148
Topic: Risk factors for breast cancer
PurposeNeoadjuvant chemotherapy has traditionally been used for locally-advanced breast cancer and to facilitate breast-conserving-therapy. Several studies have shown an association between pathological complete response (pCR) and improved overall survival. However, in patients who don't achieve pCR, their survival has not been addressed with a great degree of specificity. Neo-Biocsore is one of the ways to evaluate prognosis after neoadjuvant therapy, utilizing the clinical and pathological variables. The aim of this study was to assess the application of Neo-Bioscore in UK cohort of breast cancer patients receiving neoadjuvant chemotherapy.Patients and MethodsCharts of breast cancer patients treated with neoadjuvant chemotherapy from 2009 to 2013 were reviewed for clinical and pathological tumor characteristics, treatment and patient outcomes. Complete data was available for 76 patients. Survival predicted by clinical stage, pathological stage and Neo-Bioscore was calculated using the Kaplan-Meier method, (significance set at P < .05). All calculations were performed with SPSS version-19. Results: Median follow-up was 53 months (range, 11-101months). Five-year disease-specific survival rate was 89% for patients who achieved a pathological complete response (n =14) compared with 46% for patients who did not achieve a pCR (n = 61; P = 0.05). 5-year disease-specific survival estimates ranged from 33% to 100% (P = 0.000) for Neo-Bioscore vs. 50% to 87% (P = 0.405) for presenting clinical stage, 10% to 89% (P = 0.00) for pathological stage.ConclusionNeo-Bioscore based on clinical stage, response to therapy, and biologic sub-type best defines prognosis for breast cancer patients treated with neoadjuvant chemotherapy.
Topic: Risk factors for breast cancer
PurposeNeoadjuvant chemotherapy has traditionally been used for locally-advanced breast cancer and to facilitate breast-conserving-therapy. Several studies have shown an association between pathological complete response (pCR) and improved overall survival. However, in patients who don't achieve pCR, their survival has not been addressed with a great degree of specificity. Neo-Biocsore is one of the ways to evaluate prognosis after neoadjuvant therapy, utilizing the clinical and pathological variables. The aim of this study was to assess the application of Neo-Bioscore in UK cohort of breast cancer patients receiving neoadjuvant chemotherapy.Patients and MethodsCharts of breast cancer patients treated with neoadjuvant chemotherapy from 2009 to 2013 were reviewed for clinical and pathological tumor characteristics, treatment and patient outcomes. Complete data was available for 76 patients. Survival predicted by clinical stage, pathological stage and Neo-Bioscore was calculated using the Kaplan-Meier method, (significance set at P < .05). All calculations were performed with SPSS version-19. Results: Median follow-up was 53 months (range, 11-101months). Five-year disease-specific survival rate was 89% for patients who achieved a pathological complete response (n =14) compared with 46% for patients who did not achieve a pCR (n = 61; P = 0.05). 5-year disease-specific survival estimates ranged from 33% to 100% (P = 0.000) for Neo-Bioscore vs. 50% to 87% (P = 0.405) for presenting clinical stage, 10% to 89% (P = 0.00) for pathological stage.ConclusionNeo-Bioscore based on clinical stage, response to therapy, and biologic sub-type best defines prognosis for breast cancer patients treated with neoadjuvant chemotherapy.
P148
Topic: Risk factors for breast cancer
PurposeNeoadjuvant chemotherapy has traditionally been used for locally-advanced breast cancer and to facilitate breast-conserving-therapy. Several studies have shown an association between pathological complete response (pCR) and improved overall survival. However, in patients who don't achieve pCR, their survival has not been addressed with a great degree of specificity. Neo-Biocsore is one of the ways to evaluate prognosis after neoadjuvant therapy, utilizing the clinical and pathological variables. The aim of this study was to assess the application of Neo-Bioscore in UK cohort of breast cancer patients receiving neoadjuvant chemotherapy.Patients and MethodsCharts of breast cancer patients treated with neoadjuvant chemotherapy from 2009 to 2013 were reviewed for clinical and pathological tumor characteristics, treatment and patient outcomes. Complete data was available for 76 patients. Survival predicted by clinical stage, pathological stage and Neo-Bioscore was calculated using the Kaplan-Meier method, (significance set at P < .05). All calculations were performed with SPSS version-19. Results: Median follow-up was 53 months (range, 11-101months). Five-year disease-specific survival rate was 89% for patients who achieved a pathological complete response (n =14) compared with 46% for patients who did not achieve a pCR (n = 61; P = 0.05). 5-year disease-specific survival estimates ranged from 33% to 100% (P = 0.000) for Neo-Bioscore vs. 50% to 87% (P = 0.405) for presenting clinical stage, 10% to 89% (P = 0.00) for pathological stage.ConclusionNeo-Bioscore based on clinical stage, response to therapy, and biologic sub-type best defines prognosis for breast cancer patients treated with neoadjuvant chemotherapy.
Topic: Risk factors for breast cancer
PurposeNeoadjuvant chemotherapy has traditionally been used for locally-advanced breast cancer and to facilitate breast-conserving-therapy. Several studies have shown an association between pathological complete response (pCR) and improved overall survival. However, in patients who don't achieve pCR, their survival has not been addressed with a great degree of specificity. Neo-Biocsore is one of the ways to evaluate prognosis after neoadjuvant therapy, utilizing the clinical and pathological variables. The aim of this study was to assess the application of Neo-Bioscore in UK cohort of breast cancer patients receiving neoadjuvant chemotherapy.Patients and MethodsCharts of breast cancer patients treated with neoadjuvant chemotherapy from 2009 to 2013 were reviewed for clinical and pathological tumor characteristics, treatment and patient outcomes. Complete data was available for 76 patients. Survival predicted by clinical stage, pathological stage and Neo-Bioscore was calculated using the Kaplan-Meier method, (significance set at P < .05). All calculations were performed with SPSS version-19. Results: Median follow-up was 53 months (range, 11-101months). Five-year disease-specific survival rate was 89% for patients who achieved a pathological complete response (n =14) compared with 46% for patients who did not achieve a pCR (n = 61; P = 0.05). 5-year disease-specific survival estimates ranged from 33% to 100% (P = 0.000) for Neo-Bioscore vs. 50% to 87% (P = 0.405) for presenting clinical stage, 10% to 89% (P = 0.00) for pathological stage.ConclusionNeo-Bioscore based on clinical stage, response to therapy, and biologic sub-type best defines prognosis for breast cancer patients treated with neoadjuvant chemotherapy.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}